UK markets closed

Celyad SA (CYAD.BR)

Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
0.3510-0.0040 (-1.13%)
At close: 05:35PM CET

Celyad SA

Axis Business Park
Rue Edouard Belin 2
Mont-Saint-Guibert 1435
Belgium
32 1 039 41 00
https://www.celyad.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees35

Key executives

NameTitlePayExercisedYear born
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BMECo-Founder, Interim CEO & Executive Director218.06kN/A1956
Mr. David GeorgesVice President of Finance & AdministrationN/AN/A1976
Sara ZelkovicCommunications & Investor Relations DirectorN/AN/AN/A
Ms. An PhanHead of LegalN/AN/A1975
Mr. Hannes IserentantHead of Intellectual PropertyN/AN/A1978
Mr. Philippe DechampsCorporate SecretaryN/AN/A1970
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Corporate governance

Celyad SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.